NCT02381730View on ClinicalTrials.gov

Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions

Polypoidal Choroidal Vasculopathy

Interventions

DRUG

Intravitreal aflibercept

Patient receive one intravitreal injection of 2mg aflibercept (as currently recommended in the treatment of AMD)

Trial Locations (3)

67000

Centre Médical de la Rétine Maison Rouge, Strasbourg

75019

Fondation Ophtalmologique A. de Rothschild, Paris

Unknown

CHU Lyon Croix Rousse, Lyon

All Listed Sponsors

lead

Fondation Ophtalmologique Adolphe de Rothschild

NETWORK

NCT02381730 - Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment | Biotech Hunter | Biotech Hunter